Author

T. Levine

Observed names: T D Levine, T Levine, T. D. Levine, TD Levine

Institutions: Beth Israel Deaconess Medical Center, Harvard University

Observed institutions: Beth Israel Deaconess Medical Center, Harvard University, University of Arizona, Duke University, Washington University in St. Louis, Hope Research Institute, Duke Medical Center, HonorHealth, Phoenix Neurological Associates, PNA Center for Neurological Research

OpenAlex ID: A5113439377

Hel-N1: an Autoimmune RNA-Binding Protein with Specificity for 3' Uridylate-Rich Untranslated Regions of Growth Factor mRNAs

1993 · T D Levine, F Gao, et al. · Molecular and Cellular Biology · 356

Mammalian homologs of Drosophila ELAV localized to a neuronal subset can bind in vitro to the 3' UTR of mRNA encoding the Id transcriptional repressor

1994 · PH King, TD Levine, et al. · Journal of Neuroscience · 169

PDF

Sensory exam with a quantitative tuning fork

2004 · A. Pestronk, J. Florence, et al. · Neurology · 117

Peripheral neuropathies in Waldenstrom's macroglobulinaemia

2006 · T Levine · Journal of Neurology Neurosurgery & Psychiatry · 96

PDF

Studies of Environmental Risk Factors in Amyotrophic Lateral Sclerosis (ALS) and a Phase I Clinical Trial of l-Serine

2017 · Walter G. Bradley, R. X. Miller, et al. · Neurotoxicity Research · 35

The 201 Trial: a placebo-controlled randomized phase 2 study of safety and tolerance of the c-Abl kinase inhibitor risvodetinib in untreated Parkinson’s disease

2026 · M. H. Werner, A. McGarry, et al. · Nature Aging · 6

PDF

Op0008 a Randomized, Double-blind, Placebo-controlled Phase Iii Trial of Ivig 10% in Patients With Dermatomyositis. the Proderm Study: Results on Efficacy and Safety

2021 · R. Aggarwal, C. Charles-Schoeman, et al. · Annals of the Rheumatic Diseases · 6

PDF

T.P.45 An ongoing phase 2a study to investigate drug–drug interactions between escalating doses of AT2220 (duvoglustat hydrochloride) and acid alpha glucosidase in subjects with Pompe disease – Preliminary results

2012 · P. Kishnani, M. Tarnopolsky, et al. · Neuromuscular Disorders · 3

Autoimmune Myopathies

2020 · R. Aggarwal, C. Charles-Schoeman, et al. · Neuromuscular Disorders · 2

P.02Phase 2/3 study of Arimoclomol in sporadic inclusion body myositis: study design

2019 · P. Machado, R. Barohn, et al. · Neuromuscular Disorders · 2

O.33Subcutaneous immunoglobulin in myasthenia gravis: results of a North American open label study

2019 · M. Pasnoor, V. Bril, et al. · Neuromuscular Disorders · 2

T.P.46 A novel phase 2a study design to investigate drug-drug interactions between escalating doses of AT2220 (duvoglustat hydrochloride) and acid alpha-glucosidase in subjects with Pompe disease

2012 · P. Kishnani, M. Tarnopolsky, et al. · Neuromuscular Disorders · 1

A Pilot Trial of Zinc in Patients with ALS (P04.153)

2012 · T. Levine, N. Hank, et al. · Neurology · 1

A Novel Diagnostic Method for Detection and Quantitation of Cutaneous Phosphorylated Alpha-Synuclein

2025 · B. Bellaire, C. Gibbons, et al. · Parkinsonism & Related Disorders

An Analysis of Biopsy Number in the Detection of Cutaneous Phosphorylated Alpha-Synuclein

2025 · T. Levine, B. Bellaire, et al. · Parkinsonism & Related Disorders

The Syn-D Study: Detection of Cutaneous Phosphorylated Alpha-Synuclein and blood P-Tau 217 in Patients with Mild Cognitive Impairment

2025 · T. Levine, B. Bellaire, et al. · Parkinsonism & Related Disorders

In-Office Intravenous Treatment for Intractable Headaches (P03.234)

2012 · R. Bland, K. Clarke, et al. · Neurology

Substitution of SCIg for IVIg in Immune-Mediated Neuropathy Patients Unable To Tolerate IVIg (P06.132)

2012 · D. Saperstein, T. Levine · Neurology

Works count: 18

Citation count: 796

H-index: 6

I10-index: 5